Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G F Baxter

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Cardiovascular Research|April 16, 1998
Ischaemic preconditioning: present position and future directionsD M Yellon, G F Baxter, D Garcia-Dorado, et al.
Heart (British Cardiac Society)|December 21, 2005
Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albuminD Roy, J Quiles, D C Gaze, et al.
Journal of Cardiovascular Pharmacology|November 15, 2001
Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPKG F Baxter, M M Mocanu, B K Brar, et al.
British Journal of Pharmacology|April 1, 1996
Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischaemic properties in rabbit heartG F Baxter, R W Goodwin, M J Wright, et al.
Basic Research in Cardiology|April 7, 2000
Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioningK A Aitchison, G F Baxter, M M Awan, et al.
Cardiovascular Research|May 1, 1996
Infarct limitation of the second window of protection in a conscious rabbit modelX M Yang, G F Baxter, R J Heads, et al.
Circulation|June 27, 2001
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxideM M Mocanu, H L Maddock, G F Baxter, et al.
Cardiovascular Drugs and Therapy|April 13, 2001
Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct studyG F Baxter, S L Hale, T Miki, et al.
Journal of the American College of Cardiology|June 13, 2001
Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardiumM T Jaberansari, G F Baxter, C A Muller, et al.
Experimental & Molecular Medicine|September 13, 2005
Representational difference analysis of cDNA identifies novel genes expressed following preconditioning of the heartM A C Fauchon, T J Pell, G F Baxter, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Cardiovascular Research|April 16, 1998
Ischaemic preconditioning: present position and future directionsD M Yellon, G F Baxter, D Garcia-Dorado, et al.
Heart (British Cardiac Society)|December 21, 2005
Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albuminD Roy, J Quiles, D C Gaze, et al.
Journal of Cardiovascular Pharmacology|November 15, 2001
Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPKG F Baxter, M M Mocanu, B K Brar, et al.
British Journal of Pharmacology|April 1, 1996
Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischaemic properties in rabbit heartG F Baxter, R W Goodwin, M J Wright, et al.
Basic Research in Cardiology|April 7, 2000
Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioningK A Aitchison, G F Baxter, M M Awan, et al.
Cardiovascular Research|May 1, 1996
Infarct limitation of the second window of protection in a conscious rabbit modelX M Yang, G F Baxter, R J Heads, et al.
Circulation|June 27, 2001
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxideM M Mocanu, H L Maddock, G F Baxter, et al.
Cardiovascular Drugs and Therapy|April 13, 2001
Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct studyG F Baxter, S L Hale, T Miki, et al.
Journal of the American College of Cardiology|June 13, 2001
Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardiumM T Jaberansari, G F Baxter, C A Muller, et al.
Experimental & Molecular Medicine|September 13, 2005
Representational difference analysis of cDNA identifies novel genes expressed following preconditioning of the heartM A C Fauchon, T J Pell, G F Baxter, et al.
Pageof 7